Study genes in people who respond unusually to treatment
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study looks at stored tumor samples to understand why some people respond much better or much worse than expected. The goal is to learn what the tumor’s genes might be telling doctors about response to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your doctor feels your treatment response was unusually good or unusually poor
- If you’re alive or treated recently, you may need tumor tissue saved from before treatment
- If you are deceased, the study can still use stored tumor samples (limited numbers per year)
- The tumor sample must be enough for genetic testing (sequencing)
- There are no listed exclusion conditions in the provided eligibility info
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies advanced solid tumors by using stored tumor samples to look for molecular clues. The goal is to help doctors better choose cancer treatments that may work for your specific tumor.
This study tests the genes of your cancer to learn more about advanced breast, lung, melanoma, or sarcoma tumors. It may help doctors find better ways to treat these cancers in the future.
This study uses advanced DNA testing on tumor samples to help match cancer treatments more precisely. It may help researchers learn which cancer changes are driving your tumor and how they relate to treatment choices.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study looks at why some breast cancers stop responding to treatment. It involves taking a small sample of your tumor (biopsy) and blood to understand resistance. If you have HER2-positive or triple-negative breast cancer that is growing despite treatment, you may be able to join.
This study looks for cancer-related material in blood, urine, and sometimes bone marrow. It may help researchers understand how to detect cancer activity and track it over time using less invasive tests.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.